No other insider has filed at W. Michael Flanagan's companies, so these are insiders reporting open-market trades at other companies in the same sector.
W. Michael Flanagan is a corporate insider, tracked as Director of Atrium Therapeutics, Inc. (RNA). InsiderAlpha holds 8 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has W. Michael Flanagan submitted recently?
1 primary Form 4 filing in the last 90 days, covering 1 company.
Has W. Michael Flanagan been buying or selling stock?
Recorded transactions: 0 open-market purchases and 6 open-market sales ($5.50M) across all tracked filings.
W. Michael Flanagan is Director of Atrium Therapeutics, Inc. (RNA). 8 SEC Form 4 filings on record going back to 2024, most recently on 22 September 2026. Most recent open-market trade: sold $185K of RNAM on 23 January 2026. Lifetime open-market sales: $5.50M.
Recent transactions
11
The latest 11 SEC Form 4 transactions reported by W. Michael Flanagan.
InsiderAlpha's records for W. Michael Flanagan go back to 2024: 8 primary Form 4 filings, an average of 2.7 per year. 9 recorded transactions carry a Rule 10b5-1 plan flag. This identifies the marked transactions as reported under a trading plan; it does not establish the plan status of unmarked transactions.
